Teachers Retirement System of The State of Kentucky Has $45.04 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Teachers Retirement System of The State of Kentucky trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 96,836 shares of the pharmaceutical company’s stock after selling 1,809 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Vertex Pharmaceuticals were worth $45,037,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of VRTX. Northwest Investment Counselors LLC bought a new stake in Vertex Pharmaceuticals during the third quarter worth $25,000. Dunhill Financial LLC lifted its position in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the last quarter. Highline Wealth Partners LLC acquired a new stake in Vertex Pharmaceuticals in the third quarter valued at about $27,000. GHP Investment Advisors Inc. bought a new position in Vertex Pharmaceuticals in the second quarter valued at about $29,000. Finally, Legacy Investment Solutions LLC acquired a new position in Vertex Pharmaceuticals during the third quarter worth about $33,000. 90.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Canaccord Genuity Group lifted their price target on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a report on Wednesday, November 6th. Oppenheimer dropped their price target on Vertex Pharmaceuticals from $550.00 to $540.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. HC Wainwright reaffirmed a “buy” rating and issued a $600.00 target price on shares of Vertex Pharmaceuticals in a report on Monday, October 21st. UBS Group increased their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Finally, Bank of America lowered their price objective on Vertex Pharmaceuticals from $550.00 to $541.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $506.20.

Vertex Pharmaceuticals Trading Down 1.0 %

Shares of Vertex Pharmaceuticals stock opened at $469.22 on Wednesday. The stock has a market capitalization of $120.84 billion, a PE ratio of -235.79 and a beta of 0.36. Vertex Pharmaceuticals Incorporated has a 52 week low of $351.44 and a 52 week high of $519.88. The stock has a 50 day moving average price of $473.01 and a two-hundred day moving average price of $475.84. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter last year, the firm posted $3.67 EPS. Vertex Pharmaceuticals’s revenue was up 11.6% compared to the same quarter last year. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.